<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30146252</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-2157</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>44</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>10</Month>                    </PubDate>                </JournalIssue>                <Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title>                <ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis.</ArticleTitle>            <Pagination>                <MedlinePgn>1504-1512</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0748-7983(18)31269-1</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2018.08.002</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVE">The impact of primary tumor resection (PTR) on survival is still controversial in stage IV breast cancer. This systematic review and meta-analysis aimed to evaluate the impact of PTR on overall survival (OS) in stage IV breast cancer.</AbstractText>                <AbstractText Label="METHODS">Comprehensive literature search was conducted to identify studies comparing PTR with no PTR for stage IV breast cancer. The quality of the studies was assessed using Cochrane risk of bias tool and Newcastle-Ottawa Scale. We used subgroup and meta-regression analysis to assess the contribution of demographic and clinical factors to heterogeneity.</AbstractText>                <AbstractText Label="RESULTS">Data on 714 patients in 3 randomized controlled trials (RCTs) and 67,272 patients in 30 observational studies were included. One RCT was terminated early due to poor recruitment, and the remaining two RCTs' design were different, thus RCTs were only performed systematic review without meta-analysis. The pooled outcomes of 30 observational studies showed PTR significantly improved OS (HR = 0.65; 95%CI, 0.61 to 0.70, P &lt; 0.001, I<sup>2</sup> = 80%). Additionally, PTR was associated with better distant progression-free survival (HR = 0.42; 95%CI, 0.29 to 0.60) but did not impact progression-free survival. Subgroup analysis showed PTR benefit in patients who had only one metastatic site (HR = 0.62, 95%CI. 0.48 to 0.81), bone-only metastasis (HR = 0.61, 95%CI. 0.37 to 1.00), with negative margin (HR = 0.61, 95%CI. 0.58 to 0.65).</AbstractText>                <AbstractText Label="CONCLUSIONS">PTR should not be part of routine clinical practice in stage IV breast cancer but might be performed in selected patients. Our findings highlight PTR might be valuable in patients with limited disease burden or attaining clear margin.</AbstractText>                <CopyrightInformation>Copyright © 2018. Published by Elsevier Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Xiao</LastName>                    <ForeName>Weikai</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zou</LastName>                    <ForeName>Yutian</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zheng</LastName>                    <ForeName>Shaoquan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Xiaoqian</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Rehabilitation Science, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Peng</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Xinhua</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yu</LastName>                    <ForeName>Ping</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tang</LastName>                    <ForeName>Hailin</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China. Electronic address: tanghl@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Xiaoming</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, People's Republic of China. Electronic address: xiexm@sysucc.org.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D017418">Meta-Analysis</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Eur J Surg Oncol</MedlineTA>            <NlmUniqueID>8504356</NlmUniqueID>            <ISSNLinking>0748-7983</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018567" MajorTopicYN="N">Breast Neoplasms, Male</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Meta-analysis</Keyword>            <Keyword MajorTopicYN="Y">Primary tumor resection</Keyword>            <Keyword MajorTopicYN="Y">Stage IV breast cancer</Keyword>            <Keyword MajorTopicYN="Y">Systematic review</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30146252</ArticleId>            <ArticleId IdType="pii">S0748-7983(18)31269-1</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejso.2018.08.002</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>